Health security is usually discussed in terms of hospitals, doctors and surveillance systems. It is less often discussed in terms of whether the medicine exists in the country when it is needed. Yet the second question determines whether the first three matter.
Bangladesh manufactures roughly 98 percent of the medicine it consumes. That figure is not just an industrial statistic. It is a strategic position, and it was built deliberately.
The Lesson of Supply Shocks
Countries that import most of their medicine discovered something uncomfortable during the COVID-19 period: in a crisis, exporting countries protect their own populations first.
Export restrictions appeared on active pharmaceutical ingredients and finished products. Freight capacity collapsed and costs multiplied. Lead times that were normally four weeks became four months. Countries at the back of the queue — small markets, low-margin buyers, those without domestic production — waited.
For a nation of 170 million people, being at the back of that queue is not an inconvenience. It is a public health emergency in slow motion: antibiotic stockouts, interrupted chronic disease treatment, unavailable paediatric formulations.
Bangladesh was substantially insulated from this because it makes its own medicine. That insulation is the practical meaning of health security.
What Domestic Manufacturing Actually Protects Against
Supply interruption
A domestic manufacturer can respond to a demand spike in weeks. An importer has to negotiate allocation with a foreign supplier who has other customers and possibly a government instructing them where to ship first.
Currency volatility
When a country imports finished medicine, every depreciation of the taka raises the cost of every dose. Local manufacture confines that exposure to imported inputs, which represent a fraction of finished value. This is one of the largest structural protections domestic production provides, and it operates continuously rather than only in crises.
Price shocks
Domestic competition among a large number of manufacturers producing around 8,000 generic products keeps prices under pressure in a way that import markets rarely replicate.
Product mix mismatch
Foreign manufacturers make what their main markets demand. Local manufacturers make what local patients need — the disease burden, the climate-appropriate formulations, the pack sizes people can afford, the paediatric and tropical-disease products that global suppliers may deprioritise.
Regulatory reach
A domestic regulator can inspect a domestic factory. It can suspend a licence, order a recall, prosecute under the Drugs and Cosmetics Act 2023, and require corrective action. Against a foreign manufacturer, its leverage is limited to refusing entry — which protects future shipments but does nothing about the product already in the market.
The Secondary Benefits Are Not Small
Employment. The pharmaceutical sector is the country’s largest white-collar employer, absorbing pharmacists, chemists, microbiologists, engineers and quality professionals.
Skills retention. A functioning domestic industry gives science graduates a reason to build careers at home. That accumulated expertise is what makes the next stage — biosimilars, complex generics, vaccines — possible at all.
Export earnings. Pharmaceutical exports reached roughly 213 million US dollars in FY2024-25 across more than 160 countries. Alongside agro-processing and light engineering, pharmaceuticals is one of the sectors identified for reducing dependence on ready-made garments, which currently account for over 80 percent of merchandise exports.
Crisis response capability. A country with formulation capacity can respond to a novel outbreak in a way an importer cannot, provided the regulatory and raw material foundations exist.
The Weak Point: Active Pharmaceutical Ingredients
Here is the honest limit of Bangladesh’s self-sufficiency.
The country manufactures finished medicines domestically, but imports 80 to 90 percent of its active pharmaceutical ingredients, mostly from India and China. Bangladesh has secured formulation independence while remaining dependent for the chemistry that goes into the formulation.
That matters because it means the supply shock risk has been moved upstream, not eliminated. If API exports from a supplier country are restricted, Bangladeshi factories can be fully staffed, fully certified and completely idle.
It also has ongoing cost effects. Import dependency exposes local manufacturers to global price fluctuations and supply chain vulnerability, and it caps the value added domestically.
What is being done
The API Industrial Park at Gazaria in Munshiganj is the principal response. Established by the Bangladesh Small and Cottage Industries Corporation on 200 acres, with plots allocated to manufacturers and a common effluent treatment plant, the park was intended to build domestic ingredient capacity ahead of LDC graduation.
Progress has been slower than planned. The project began in 2008 and is still not fully operational. Irregular gas supply has been the persistent obstacle — companies with completed facilities have struggled to begin production without reliable utilities. Several major manufacturers, including ACME Laboratories, Healthcare Pharmaceuticals, Ibn Sina Pharmaceuticals and Unimed-UniHealth Fine Chemicals, have established plants there, and commissioning has begun despite the constraints.
Analysts are direct about the diagnosis: without dependable utility services, API production will not gain momentum. This is an infrastructure problem more than an industrial one.
Vaccines: The Gap That Is Still Open
Vaccine production in Bangladesh began in 2011. Three companies — Incepta, Popular and Healthcare — produce 15 to 16 types of human and animal vaccines. Only Incepta exports, in small quantities to a few African countries.
The constraint is regulatory rather than technical. Widescale vaccine export requires WHO Maturity Level 3 certification of the national regulatory authority, signifying that it is stable, well-managed and internationally recognised. The DGDA has been working toward this since 2016 and has made progress across the evaluated areas, but certification remains out of reach, leaving Bangladesh largely excluded from global vaccine procurement markets.
Essential Drugs Company Limited is establishing the country’s first dedicated vaccine plant in Munshiganj, with plans to produce 15 vaccines including HPV and Japanese encephalitis. Pandemic preparedness in any meaningful sense depends on both the plant and the certification arriving.
The 2026 Pressure Point
Bangladesh is scheduled to graduate from least developed country status on 24 November 2026, forfeiting the WTO TRIPS pharmaceutical waiver that has allowed local production of patented molecules without licences. The government has requested a three-year deferment to 2029.
The health security implication is specific. The waiver has been part of what makes newer, expensive treatments producible locally. Without it, roughly one-fifth of the domestic pipeline — disproportionately the newer, higher-value molecules — requires patent clearance or licensing. Where licensing is unaffordable or unavailable, those products become imports again, at import prices, with import supply risk.
This is why the API park, DGDA modernisation, R&D investment and legal preparedness are being discussed together. They are all parts of the same question: can Bangladesh hold its medicine self-sufficiency once the legal shortcut closes?
What Manufacturers Can Contribute
Health security is largely a policy matter, but individual manufacturers affect it directly.
Producing across the essential medicines list, including low-margin products that are clinically important but commercially unglamorous.
Maintaining buffer capacity rather than running every line at maximum utilisation, so that demand spikes can be absorbed.
Diversifying raw material suppliers across countries, so that a single export restriction does not stop production.
Building genuine quality systems — tested raw materials, documented batch records with in-process checks, finished goods tested before release, traceability from raw material to dispatch. Domestic supply that cannot be trusted provides no security at all.
Deep nationwide distribution. A medicine that exists in a Dhaka warehouse but not in a district pharmacy is not accessible to the patient who needs it.
Extending the same discipline to consumer health products. Safe drinking water, hygiene products and hygienically produced food prevent illness that would otherwise become treatment demand.
Frequently Asked Questions
What share of Bangladesh’s medicine is locally made?
Approximately 98 percent of domestic demand is met by local manufacturers.
If we make our own medicine, why do we still depend on imports?
Because 80 to 90 percent of active pharmaceutical ingredients are imported. Formulation is domestic; the underlying chemistry largely is not.
What is the API Park and why does it matter?
An industrial zone at Gazaria in Munshiganj dedicated to producing active pharmaceutical ingredients domestically, intended to reduce import dependency. Utility supply constraints have delayed full operation.
Why can’t Bangladesh export vaccines widely?
Widescale vaccine export requires WHO Maturity Level 3 certification of the national regulatory authority, which the DGDA has not yet achieved.
Does local manufacturing mean lower quality?
No. Quality is a function of the individual manufacturer’s systems, not of geography. Bangladeshi facilities hold approvals from regulators including the US FDA and the UK MHRA.
Closing
Local pharmaceutical manufacturing is the reason Bangladesh’s medicine supply held during a global crisis, the reason common medicines remain affordable, and the reason a domestic regulator has real leverage over what reaches patients. The unfinished work is upstream: active ingredients, regulatory maturity and the capacity to develop rather than only replicate.
PROMIXCO Pharmaceutical Limited manufactures medicines, toiletries, cosmetics and food and beverage products in its own production unit in Bangladesh, supplying pharmacies, distributors, retail chains, hospitals and institutional buyers nationwide.
For supply, distribution or institutional enquiries: info@promixcopl.com.
